Study #2023-0799
Safety and feasibility of autologous CD34+ hematopoietic stem cells mobilization and apheresis in participants with RUNX1 familial platelet disorder
MD Anderson Study Status
Enrolling
Treatment Agent
G-CSF (filgrastim or biosimilar), Plerixafor
Description
To evaluate the safety and feasibility of collecting hematopoietic stem cells (HSC) in participants with RUNX1-FPD.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
RUNX1 Familial Platelet Disorder
Study phase:
Phase I
Physician name:
Chitra Hosing
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-855-996-1481
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.